Kumar Neil's Insider Trades & SAST Disclosures
Kumar Neil's most recent trade in BridgeBio Pharma Inc was a trade of 37,899 Common Stock done at an average price of $33.4 . Disclosure was reported to the exchange on Feb. 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kumar Neil.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.36 per share. | 25 Feb 2025 | 37,899 | 5,060,548 (4%) | 0% | 33.4 | 1,264,447 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.79 per share. | 25 Feb 2025 | 37,101 | 5,023,447 (4%) | 0% | 33.8 | 1,253,524 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 55,539 | 267,257 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 33,544 | 268,352 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.14 per share. | 16 Feb 2025 | 31,467 | 211,794 (0%) | 0% | 36.1 | 1,137,246 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.90 per share. | 16 Feb 2025 | 23,996 | 243,261 (0%) | 0% | 34.9 | 837,460 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 19,600 | 235,191 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 2,395 | 0 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.57 per share. | 16 Feb 2025 | 76 | 211,718 (0%) | 0% | 36.6 | 2,779 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.29 per share. | 28 Jan 2025 | 326,932 | 5,371,515 (4%) | 0% | 36.3 | 11,863,381 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.34 per share. | 28 Jan 2025 | 269,068 | 5,102,447 (4%) | 0% | 36.3 | 9,777,985 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.82 per share. | 28 Jan 2025 | 4,000 | 5,098,447 (4%) | 0% | 36.8 | 147,284 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Dec 2024 | 4,685,725 | 211,718 (0%) | 3% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Dec 2024 | 4,685,725 | 5,698,447 (4%) | 3% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 121,951 | 121,951 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.39 per share. | 19 Nov 2024 | 25,514 | 4,899,318 (3%) | 0% | 22.4 | 571,146 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.76 per share. | 19 Nov 2024 | 1,875 | 4,897,443 (3%) | 0% | 22.8 | 42,680 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2024 | 55,537 | 4,952,980 (4%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2024 | 33,544 | 301,896 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 16 Nov 2024 | 28,148 | 4,924,832 (3%) | 0% | 23.7 | 667,671 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2024 | 19,599 | 254,791 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2024 | 2,394 | 2,395 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 55,537 | 4,952,980 (4%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 33,544 | 335,440 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.40 per share. | 16 Aug 2024 | 28,148 | 4,924,832 (3%) | 0% | 24.4 | 686,811 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 19,599 | 274,390 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.39 per share. | 16 Aug 2024 | 16,192 | 4,897,443 (3%) | 0% | 24.4 | 394,889 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 16 Aug 2024 | 11,197 | 4,897,443 (3%) | 0% | 25.1 | 281,367 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 2,394 | 4,789 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 60,667 | 4,928,191 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 33,544 | 368,984 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.04 per share. | 16 May 2024 | 30,748 | 4,897,443 (3%) | 0% | 31.0 | 954,418 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 19,599 | 293,989 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 5,130 | 0 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 2,394 | 7,183 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 313,588 | 313,588 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 45,140 | 45,140 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Kumar Neil | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 102,249 | 4,915,446 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 61,182 | 0 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Kumar Neil | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.21 per share. | 16 Feb 2024 | 47,922 | 4,867,524 (3%) | 0% | 37.2 | 1,783,178 | Common Stock |
| BridgeBio Pharma Inc | Kumar Neil | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 33,544 | 402,528 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 5,129 | 5,130 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Kumar Neil | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 2,394 | 9,577 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 102,250 | 4,915,447 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 61,182 | 122,364 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 16 Aug 2023 | 51,552 | 4,813,197 (3%) | 0% | 28.6 | 1,473,784 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.80 per share. | 16 Aug 2023 | 50,698 | 4,864,749 (3%) | 0% | 29.8 | 1,510,800 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 33,544 | 469,616 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 5,130 | 15,388 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 2,394 | 14,365 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 102,249 | 4,915,446 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 61,182 | 183,546 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.01 per share. | 16 May 2023 | 51,552 | 4,813,197 (3%) | 0% | 14.0 | 722,218 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.09 per share. | 16 May 2023 | 50,697 | 4,864,749 (3%) | 0% | 14.1 | 714,321 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 33,544 | 503,160 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 5,129 | 20,518 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 2,394 | 16,759 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.18 per share. | 03 May 2023 | 120,000 | 1,012,722 (0%) | 0% | 14.2 | 1,701,744 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 15.46 per share. | 05 Apr 2023 | 120,000 | 1,132,722 (0%) | 0% | 15.5 | 1,855,656 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 10.96 per share. | 03 Mar 2023 | 120,000 | 1,252,722 (1%) | 0% | 11.0 | 1,315,224 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 68,706 | 4,881,903 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 61,182 | 244,728 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 12.70 per share. | 16 Feb 2023 | 44,798 | 4,813,197 (3%) | 0% | 12.7 | 569,073 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.64 per share. | 16 Feb 2023 | 23,908 | 4,857,995 (3%) | 0% | 12.6 | 302,197 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 5,129 | 25,647 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 2,395 | 19,153 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 11.01 per share. | 03 Feb 2023 | 120,000 | 1,372,722 (1%) | 0% | 11.0 | 1,320,696 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 05 Jan 2023 | 120,000 | 1,492,722 (1%) | 0% | 7.7 | 920,856 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 21 Dec 2022 | 200,000 | 995,686 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 68,705 | 4,840,894 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 61,182 | 367,092 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.08 per share. | 16 Aug 2022 | 27,697 | 4,813,197 (3%) | 0% | 11.1 | 306,883 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 5,129 | 35,906 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 2,394 | 23,942 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 68,705 | 4,795,948 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 61,182 | 428,274 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 16 May 2022 | 23,759 | 4,772,189 (3%) | 0% | 6.7 | 160,136 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 5,129 | 41,035 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 2,394 | 26,336 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 489,456 | 489,456 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 7,524 | 4,730,328 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 5,130 | 46,164 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 16 Feb 2022 | 3,085 | 4,727,243 (3%) | 0% | 8.8 | 27,271 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 2,394 | 28,730 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 7,523 | 4,726,534 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 5,129 | 51,294 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.25 per share. | 16 Nov 2021 | 3,730 | 4,722,804 (3%) | 0% | 47.3 | 176,243 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 2,394 | 31,124 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 7,523 | 4,722,741 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 5,129 | 56,423 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.48 per share. | 16 Aug 2021 | 3,730 | 4,719,011 (3%) | 0% | 49.5 | 184,560 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 2,394 | 33,518 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2021 | 7,524 | 4,718,949 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2021 | 5,130 | 61,552 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.66 per share. | 16 May 2021 | 3,731 | 4,715,218 (3%) | 0% | 53.7 | 200,205 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2021 | 2,394 | 35,912 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.50 per share. | 16 Feb 2021 | 16,000 | 4,711,425 (3%) | 0% | 62.5 | 1,000,000 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 5,129 | 4,697,564 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 5,129 | 66,682 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.98 per share. | 16 Feb 2021 | 2,139 | 4,695,425 (3%) | 0% | 65.0 | 138,992 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 624,652 | 624,652 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges